Expert Interview
Examining the IPF treatment landscape with a focus on Pliant's bexotegrast, Fibrogen's pamrevlumab, and United Therapeutics' TYVASO (treprostinil)
Ticker(s): FGEN, PLRX, UTHRInstitution - Blessing Health System/ Hannibal Clinic
- Pulmonologist (Board-certified in Critical Care Medicine, Internal Medicine, Pulmonary Disease and Sleep Medicine); fellowship trained at University of Chicago.
- Manages over 500 patients with a variety of pulmonary conditions including IPF.
- Serves as the head of research at the Blessing Heath Hannibal clinic and on the editorial board for the Journal of Virology Research and Reports.
How do each of these three treatments differ in their mechanism of action and do any of them stand out to you as a preferred method?
Added By: max_adminPliant Therapeutics is developing bexotegrast, which works on a different target from the approved drugs. What are your thoughts on this target and the data that they have generated so far?
What are your thoughts on bexotegrast target and the data that they have generated so far?
How would you describe the current standard of care, the available treatments and the unmet needs in this space?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
